Astex announces drug discovery alliance with Boehringer Ingelheim

09-Mar-2004

Cambridge, UK. Astex Technology, the fragment-based drug discovery company, announced a three year, multi-target-based, alliance with Boehringer Ingelheim for the discovery of novel drugs for various therapeutic indications. This new collaboration, will apply Astex's proprietary fragment based discovery approach, Pyramid(TM), to generate novel lead series against targets selected by Boehringer Ingelheim. Boehringer Ingelheim will be responsible for all clinical development and has an option to obtain worldwide exclusive marketing rights for all identified compounds.

Under the terms of the agreement, Boehringer Ingelheim will make an upfront payment to Astex for access to its Pyramid(TM) technology, will fund the research programmes and will provide milestone payments plus royalties based on the sales of approved products.

"We are delighted that Boehringer Ingelheim has chosen Astex for this significant collaboration," commented Timothy Haines, Chief Executive of Astex. "This provides further validation of Astex's world-leading position in fragment-based drug discovery, and underscores the potential of our Pyramidä approach for developing novel lead compounds against important disease-related targets."

Professor Dieter Hinzen, Head of R&D at Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, said "Astex's fragment based Pyramid(TM) approach nicely complements our internal technology portfolio for the discovery and optimization of lead compounds for targets in areas of unmet therapeutic need. This cooperation underlines BI's commitment as a research driven company to provide innovative drugs to the patient."

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance